GB
General Biologic
General Biologic www.generalbiologic.com
集博使命: 为客户评估、把握以及开拓生物技术产业内的宝贵机遇,传播卓越、进取、创新的文化。
集博客户: 包括投资商、医药公司、生物技术公司,以及科研仪器、试剂和耗材的供应商。
集博服务: 包括管理咨询、投资融资服务、投资管理以及撰写并出版行业分析报告。
集博团队:集博员工具有多年在中美生物技术/医药行业工作的经验,多数拥有生命科学领域硕士或博士学历。
Matthew Chervenak 是集博公司的总裁及创立者。他曾在美国卫生院(NIH)牙科研究所、美国眼科研究所以及纽约大学医学中心从事分子生物学研究,随后在世界著名咨询公司Sapient Corporation担任战略咨询顾问,专门为纽约的小型企业以及投资银行提供服务。2002年,Chervenak创立了集博公司。
公司性质: 集博(上海集博投资管理咨询有限公司)是一家外商独资企业,这一身份使我们可以便利地为国内外的客户提供服务。
GB’s clients include industry participants and investors engaged in the pharmaceutical, biotechnology and healthcare industries.
Our team:
Our multidisciplinary team includes Chinese and Westerners with industry and scientific backgrounds. The mix of business and science, East and West, makes us a truly unique firm in the marketplace. Our dedication to excellence, learning, and innovation creates an exceptional work environment.
Matthew Chervenak is president and founder of GB. His scientific experience includes molecular biology research at the National Institute of Dental Research, the National Eye Institute, and New York University Medical Center. He has worked as a strategy consultant at Sapient Corporation serving startup and investment banking clients in New York City. He founded GB in 2002.
Structure within China:
GB (Shanghai GB Investment Management Consulting Co. Limited) is a Wholly Owned Foreign Enterprise in China.